Reading TTRX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TTRX free→Turn Therapeutics Inc (TTRX)
NASDAQHealth CareBiotechnologySnapshot 2026-07-06
Watch· this week
$7.69+8.01%
Close 2026-07-06 · 1-day change
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
The bottom line
The thesis is that TTRX's product launch keeps compounding. The positive study results support market entry. TTRX trades at an undefined multiple with no peer comparison available. The lack of earnings history raises concerns about future performance. This read is provisional.
as of 2026-07-06
Quick facts
- Exchange
- NASDAQ
- Sector
- Health Care
- Industry
- Biotechnology
- Market cap
- $212.09M
- Employees
- —
- IPO date
- 2025-09-02
- Next earnings
- 2026-08-10
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 0 valuation methods, at three horizons. Current price $7.69. As of 2026-07-06. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Fair value· primary
—
Range — – —
vs price: —
Method agreement —
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
3-year
—consensus
Range — – —
vs price: —
Method agreement —
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
5-year
—consensus
Range — – —
vs price: —
Method agreement —
A long-thesis check that carries the widest uncertainty of the three horizons.
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
12-month view
Not enough valuation methods to set a 12-month read yet.
Compared to peers
Not enough peers to compare yet.
Compared to its own history
Self-history needs ~20 months of data.
P/E
—
EV/EBITDA
—
FCF yield
—
Earnings yield (TTM)
Long-term · 1–3 yrHow strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
weakOperating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 30% of the time over the next year (vs 50% for the rest of the cohort, n=9274).
5th pctl · Health Care
Earnings quality
Not enough signal yet.
Macro sensitivity
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates.
Management & capital allocation
neutral7 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 48% for the rest of the cohort, n=4965).
66th pctl · Health Care
Earnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Earnings setup · pre-print positioning
forward-looking
Neutral1 analysts, 100% Buyfor period ending 2026-09-30
Why this setup
Consensus revisions
EPS estimate $-0.02 → $-0.02 (+0.0% / 30d). 0 raised, 0 cut, 1 covering analysts.
Rating actions
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
Sector context
Intermediate · WeeklySector phase: health care is in maturing, with decelerating (~0.5 years in phase).
Sector regime (90d momentum): headwind.Secular epoch: Mature by revenue growth · theme AI-drug-discovery.headwind
Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Provisional
- Post-call reaction
- strong
A guidance track record builds as the company issues and delivers on guidance.
as of 2026-07-06
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Long-term · 1–3 yr
- #1
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$237.
How much price usually moves either way.
On a bad day, this stock has moved -$962.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $7,054.
Deepest peak-to-trough drop in the last year.
highas of 2026-07-06
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- No material changes since the prior snapshot.
Yes, our read has strengthened. The positive results from the GX-03 dermatitis study support product viability and market entry, which enhances the outlook for TTRX. There are no current threats noted that would weaken this assessment.
as of 2026-07-06
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Intermediate · Weekly
- DownsideHigh confidenceMonthsactive 17d
Watch for Q2 earnings report on August 13, 2026
Why it matters: This report will show if Turn Therapeutics is managing its losses better. Investors will look for signs of improved cash flow and reduced net income losses.
What confirms / what disproves
Confirms:Q2 earnings show net income losses of less than -$1M.
Disproves:Net income losses are over -$1M. This shows financial health is getting worse.
Sector context
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
- 2026-05-271mo agoInvesting.com India
Positive study results support product viability and market entry.
Strongly reinforcesUnconfirmed report
This sector is also watching
- Watch for Health Care revenue growth to re-accelerate above 10%
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like VRTX, REGN, and ARGX keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting TTRX and other Healthcare names. Worth watching these names for early signals.
- If the Fed starts cutting rates from the current 3.63%, that would be a tailwind for TTRX and other Healthcare names, since rate-sensitive parts of the market tend to rally when the Fed eases.
Downside triggers
- If sector bellwethers like VRTX, REGN, and ARGX start missing or guiding lower, the Healthcare tailwind helping TTRX and other Healthcare names could fade. Watch these names for early warning.
- If TTRX misses again next quarter like this past one (a solid miss of -20% on the 2026-03-31 print), expect continued pressure. The Street usually keeps walking estimates down after consecutive misses.
- If GDP growth slows materially from the current 2.7% (say, below 2%), it hits TTRX and other Healthcare names harder than the average stock, since the sector is growth-sensitive.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-111mo agoItem 2.02
of this Current Report on Form 8-K and the Press Release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Earnings preannouncementnegative
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
No score history yet for this stock.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.